Ibramvibart

伊布拉韦拜单抗

Report date: 2025/11/11 17:45:17

Base Information

Drug NameIbramvibart
Drug Alias NameVYD-2311
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionVirus internalization inhibitorsSARS-CoV-2 Spike glycoprotein receptor binding domain antagonists
TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaN/A
Originator CompaniesInvivyd Inc
China Registration ClassN/A

Develop Information

Active CompaniesInvivyd Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A